French AFU Cancer Committee Guidelines - Update 2026–2028: Testicular germ cell cancer - 20/11/26
, Aude Fléchon a, c, Nicolas Branger a, d, Pierre-Henri Savoie a, e, Laurence Rocher a, f, g, Philippe Camparo a, h, Paul Neuville a, i, Agate Escoffier a, j, Stéphane Levy a, k, Annabelle Goujon a, l, Morgan Roupret a, mAbstract |
Objective |
To update the guidelines for the management of testicular germ cell tumors.
Materials and methods |
A comprehensive literature review in PubMed was conducted for articles published from 2024 through July 2026 that addressed the diagnosis, treatment, follow-up, and treatment-related toxicity of testicular germ cell tumors (TGCTs). The level of evidence of the selected articles was assessed.
Results |
The initial evaluation of a patient with a testicular germ cell tumor is based on clinical examination, serum tumor marker assessment including Alpha-foetoprotein (AFP), total human Chorionic Gonadotrophin (hCG), and lactate deshydrogenase (LDH) levels, and imaging, including scrotal ultrasonography and contrast-enhanced computed tomography (CT) of the chest, abdomen, and pelvis. Radical inguinal orchiectomy is the first therapeutic step. It provides the histologic diagnosis, establishes the local stage, and identifies prognostic risk factors in patients with stage I nonseminomatous germ cell tumors (NSGCTs). In patients with stage I pure seminoma, the risk of relapse is 15–20%; active surveillance is therefore preferred in compliant patients. Adjuvant chemotherapy with one cycle of carboplatin at an area under the curve of 7 is an option, whereas indications for lombo-aortic radiotherapy are limited. For patients with stage I NSGCT, a risk-adapted strategy — active surveillance or one cycle of BEP chemotherapy (bleomycin, etoposide, and cisplatin), according to the absence or presence of lymphovascular invasion — is preferred over universal surveillance. Staging based on retroperitoneal lymph node dissection has a limited role. Metastatic TGCTs are most commonly treated with BEP chemotherapy, provided that bleomycin is not contraindicated. The number of cycles is determined according to the International Germ Cell Cancer Collaborative Group prognostic classification. Lombo-aortic radiotherapy and chemotherapy are both standard options for stage IIA seminomatous germ cell tumors (SGCTs) and selected low-volume stage IIB tumors. Treatment de-escalation protocols may be considered at expert centers for selected patients with metastatic stage IIA SGCT. Nerve-sparing retroperitoneal lymph node dissection at an expert center may be offered to patients with marker-negative stage IIA NSGCTs. When chemotherapy is indicated, the residual mass size must be assessed at the end of treatment by CT of the chest, abdomen, and pelvis in patients with NSGCTs. The resection of residual masses is recommended for any residual NSGCT mass larger than 1 cm. In patients with SGCTs, reassessment with 18 F-FDG PET is recommended for residual masses larger than 3 cm to guide the indication for surgery. Surgery remains uncommon in these settings. Guideline-based follow-up should be offered to all patients, together with education on testicular self-examination.
Conclusions |
Adherence to TGCT management guidelines results in excellent cancer-specific survival rates of 99% for patients with stage I disease and more than 85% for patients with metastatic disease.
Le texte complet de cet article est disponible en PDF.Keywords : Testicular cancer, Orchiectomy, Radiotherapy, Chemotherapy, Retroperitoneal lymph node dissection
Plan
Vol 36 - N° 11
Article 103223- janvier 2026 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
